文献速递骨质疏松与钙磷/甲状旁腺

双膦酸盐使用与非典型股骨骨折风险:一项带盲法影像学复核的丹麦病例-队列研究

Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case-Cohort Study With Blinded Radiographic Review.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

该研究基于丹麦全国医疗数据,纳入2010至2015年间年龄≥50岁的股骨转子下或股骨干骨折患者4973例与随机样本37021人,比较双膦酸盐使用模式与非典型股骨骨折(AFF)及髋部骨折风险。与使用不足1年相比,使用5至7年与AFF风险增加7倍相关(校正HR=7.29 [CI: 3.07, 17.30]),停药后风险迅速下降;AFF患者中31%无BP暴露。结论认为AFF风险随BP使用时间延长而增加,但BP治疗在≥50岁成人中的获益远超该风险。

要点

  • 与使用不足1年相比,双膦酸盐使用5至7年与AFF风险增加7倍相关(校正HR=7.29 [CI: 3.07, 17.30])。
  • 预防1例髋部骨折的5年需治疗人数为56,而发生1例AFF的5年需伤害人数为1424。
  • AFF患者中31%无BP暴露;糖皮质激素和质子泵抑制剂使用与AFF风险独立相关。

核心结论

  • AFF风险随双膦酸盐使用时间延长而增加,但双膦酸盐治疗在≥50岁成人中的获益远超该风险。
  • AFF患者中近三分之一无BP暴露。

研究设计与样本

  • 基于丹麦国家医疗系统的群体病例-队列研究,纳入2010至2015年间年龄≥50岁的股骨转子下或股骨干骨折患者4973例,与随机样本37021人比较。
  • 双膦酸盐使用数据采集自1995至2015年;骨折X线片(n=4769)由盲法研究放射科医师按既定标准复核识别AFF(n=189);随机样本中的传统髋部骨折(n=691)通过ICD-10识别。

主要发现

  • 与使用不足1年相比,使用5至7年与AFF风险增加7倍相关(校正HR=7.29 [CI: 3.07, 17.30]);停药后AFF风险迅速下降。
  • 预防1例髋部骨折的5年需治疗人数为56,而发生1例AFF的5年需伤害人数为1424。
  • 糖皮质激素和质子泵抑制剂使用与AFF风险独立相关。
  • AFF患者中31%无BP暴露。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prolonged bisphosphonate (BP) treatment for osteoporosis prevents hip and other fractures but causes atypical femoral fractures (AFF). OBJECTIVE: To establish the relationship between patterns of BP use and the risk of AFF and hip fractures. Other potential risk factors for AFF were also examined. METHODS: This population-based case-cohort study utilized data from the Danish National Healthcare system, including longitudinal records of medication use, healthcare utilization, and x-ray images. Among all 1.9 million Danish adults ≥50, those with subtrochanteric or femoral shaft fractures between 2010 and 2015 (n = 4973) were identified and compared to a random sample (n = 37 021). Bisphosphonate use was collected from 1995-2015. Fracture radiographs (n = 4769) were reviewed by blinded study radiologists to identify AFFs (n = 189) using established criteria. Traditional hip fractures in the random sample (n = 691) were identified by ICD-10. RESULTS: Compared to <1 year of BP use, 5 to 7 years of use was associated with a 7-fold increase in AFF (adjusted HR = 7.29 [CI: 3.07, 17.30]); the risk of AFF fell quickly after discontinuation. The 5-year number needed to harm for one AFF was 1424, while the 5-year number needed to treat to prevent one hip fracture was 56. Glucocorticoid and proton pump inhibitor use were independently associated with increased AFF risk. Thirty-one percent of those with AFF had no BP exposure. CONCLUSION: The risk of AFF increases with duration of BP use but the beneficial effects of BP therapy in adults ≥50 dramatically exceed this increased risk. Nearly one-third of those with AFF have no BP exposure.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bauer DC, Black DM, Dell R, et al. Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case-Cohort Study With Blinded Radiographic Review. J Clin Endocrinol Metab. 2024. PMID: 38198798. doi:10.1210/clinem/dgae023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。